NLRP3 and metabolic dysfunction-associated steatotic liver disease: Knockout mouse models suggested that inhibition of the NLRP3 inflammasome reduced liver inflammation, indicating that the NLRP3 inflammasome is involved in the progression of non-alcoholic fatty liver disease (NAFLD) [7,8].